BioCentury | Mar 18, 2013
Clinical News

Limtop imiquimod: Development discontinued

...showed that Limtop did not meet the predefined efficacy target. Moberg declined to disclose details. Moberg Derma AB...
BioCentury | Dec 3, 2012
Company News

Alterna, Moberg Derma deal

...nail topical solution under Alterna's brand name Kerasal Nail. Alterna LLC , Cedar Knolls, N.J. Moberg Derma AB...
BioCentury | Sep 10, 2012
Clinical News

Limtop imiquimod: Completed Phase II enrollment

...placebo-controlled, German Phase II trial evaluating topical Limtop given 1, 3 or 7 times weekly. Moberg Derma AB...
BioCentury | Aug 6, 2012
Finance

Glint of IPO optimism

...17% -60% -2% -58% RaQualia Pharma Inc. (JASDAQ:4579) 7/8/11 $79.4 -79% 10% -89% -68% -64% Moberg Derma AB...
BioCentury | Mar 19, 2012
Clinical News

Limtop: Phase I started

...Derma began a double-blind, placebo-controlled, German Phase I trial to evaluate Limtop in 30 subjects. Moberg Derma AB...
BioCentury | Mar 19, 2012
Finance

Highlights of weekly biotech stock moves

...on March 12, before the company proposed to raise $175 million in a note offering. Moberg Derma AB...
BioCentury | Feb 20, 2012
Clinical News

MOB-015: Preliminary Phase II data

...by year end. Last year, the company completed enrollment of 237 patients in the trial. Moberg Derma AB...
BioCentury | Oct 3, 2011
Finance

Cost averaging down

...NASDAQ:HZNP) 7/28/11 $49.5 $171.9 $136.5 -21% Raqualia Pharma Inc. (JASDAQ:4579) 7/8/11 $79.4 $263.2 $95.1 -64% Moberg Derma AB...
BioCentury | Sep 19, 2011
Clinical News

MOB-015: Completed Phase II enrollment

...enrollment of 237 patients in an open-label, Swedish Phase II trial evaluating once-daily topical MOB-015. Moberg Derma AB...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Hoping the rally has legs

...$2,990.2 $20,396.2 $23,307.2 7% (C) IPO performance Company Date Raised Post-$ 6/30 mcap % chg Moberg Derma AB...
Items per page:
1 - 10 of 32
BioCentury | Mar 18, 2013
Clinical News

Limtop imiquimod: Development discontinued

...showed that Limtop did not meet the predefined efficacy target. Moberg declined to disclose details. Moberg Derma AB...
BioCentury | Dec 3, 2012
Company News

Alterna, Moberg Derma deal

...nail topical solution under Alterna's brand name Kerasal Nail. Alterna LLC , Cedar Knolls, N.J. Moberg Derma AB...
BioCentury | Sep 10, 2012
Clinical News

Limtop imiquimod: Completed Phase II enrollment

...placebo-controlled, German Phase II trial evaluating topical Limtop given 1, 3 or 7 times weekly. Moberg Derma AB...
BioCentury | Aug 6, 2012
Finance

Glint of IPO optimism

...17% -60% -2% -58% RaQualia Pharma Inc. (JASDAQ:4579) 7/8/11 $79.4 -79% 10% -89% -68% -64% Moberg Derma AB...
BioCentury | Mar 19, 2012
Clinical News

Limtop: Phase I started

...Derma began a double-blind, placebo-controlled, German Phase I trial to evaluate Limtop in 30 subjects. Moberg Derma AB...
BioCentury | Mar 19, 2012
Finance

Highlights of weekly biotech stock moves

...on March 12, before the company proposed to raise $175 million in a note offering. Moberg Derma AB...
BioCentury | Feb 20, 2012
Clinical News

MOB-015: Preliminary Phase II data

...by year end. Last year, the company completed enrollment of 237 patients in the trial. Moberg Derma AB...
BioCentury | Oct 3, 2011
Finance

Cost averaging down

...NASDAQ:HZNP) 7/28/11 $49.5 $171.9 $136.5 -21% Raqualia Pharma Inc. (JASDAQ:4579) 7/8/11 $79.4 $263.2 $95.1 -64% Moberg Derma AB...
BioCentury | Sep 19, 2011
Clinical News

MOB-015: Completed Phase II enrollment

...enrollment of 237 patients in an open-label, Swedish Phase II trial evaluating once-daily topical MOB-015. Moberg Derma AB...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Hoping the rally has legs

...$2,990.2 $20,396.2 $23,307.2 7% (C) IPO performance Company Date Raised Post-$ 6/30 mcap % chg Moberg Derma AB...
Items per page:
1 - 10 of 32